On Friday, Sanofi SA (ADR) (NYSE:SNY)’s shares declined -0.98% to $47.52.
Genzyme, a Sanofi company, declared that new investigational data on its marketed treatments, Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab), in addition to data from the company’s MS pipeline, will be presented during the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The meeting, to be held in Barcelona, Spain, October 7-10th, will feature more than 50 platform and poster presentations of investigational data from across Genzyme’s MS franchise.
In addition to its marketed therapies, Genzyme has an MS R&D pipeline seeking to address unmet needs for relapsing and progressive forms of MS through research in selective immunomodulation, neuroprotection and remyelination.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Waddell & Reed Financial, Inc. (NYSE:WDR)’s shares dropped -0.83% to $34.66.
The Board of Directors of Waddell & Reed Financial, Inc. (WDR) approved a quarterly dividend on its Class A common stock of $0.43 per share payable on November 2, 2015 to stockholders of record as of October 12, 2015.
Waddell & Reed Financial, Inc. will declare third quarter 2015 earnings before trading starts on the New York Stock Exchange, Tuesday, October 27, 2015, followed by a conference call at 10:00 a.m. Eastern. To listen to this call live on the internet, visit our Web site at www.waddell.com.
Waddell & Reed Financial, Inc., through its auxiliaries, provides investment administration and advisory, investment product underwriting and distribution, and shareholder services administration to mutual funds, and institutional and separately managed accounts in the United States.
At the end of Friday’s trade, Charter Communications, Inc. (NASDAQ:CHTR)‘s shares dipped -0.76% to $183.53.
Charter Communications, Inc. (CHTR) declared that Christopher Winfrey, Executive Vice President and Chief Financial Officer, will take part in the Deutsche Bank Leveraged Finance Conference in Scottsdale, Arizona, on Tuesday, September 29, 2015. The session is planned to start at 8:40 a.m. MST (11:40 a.m. ET).
Charter Communications, Inc., through its auxiliaries, provides entertainment, information, and communications solutions to residential and commercial customers in the United States.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX), ended its Friday’s trading session with -11.51% loss, and closed at $40.76.
AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), declared the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy contrast to placebo. The trial was conducted in women with heavy menstrual bleeding (HMB) associated with uterine fibroids. Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as contrast to placebo (p
Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus.1 Fibroids are most common in women aged 30-40 years but can occur at any age. They can range in size from nearly undetectable to bulky masses that can distort the uterus. Fibroids can be asymptomatic but in some women cause symptoms such as: longer, more frequent, or heavy menstrual bleeding; menstrual pain; vaginal bleeding at time other than menstruation; pain in the abdomen or lower back; pain during sex; difficulty urinating; frequent urination; constipation or rectal pain.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
